Model Medicines at IDWeek 2026

Oct 21–24, 2026 Washington, DC ~12k attendees Website

Model Medicines brings 3 presentations to IDWeek 2026 in Washington. Its program centres on an oral antiviral candidate meant to work across flu-like illness and chronic hepatitis. In vivo studies compare it with oseltamivir, nirmatrelvir, remdesivir and sofosbuvir, and other work makes the case for a conserved pocket on the viral RNA polymerase as a broad-spectrum target.

Organization	IDWeek 2026 Attendance
Model Medicines San Diego, CA
modelmedicines.com Biotech AI-driven drug discovery company developing MDL-001, an oral broad-spectrum antiviral aimed at respiratory viruses and chronic hepatitis.	Poster Thu Oct 22 12:15pm–1:30pm The RdRp Thumb-1 pocket is a Conserved Target for Broad-Spectrum Antiviral Development Poster Hall B-C · Poster P-176 A6. New drug development (formerly L3) Poster Sat Oct 24 12:15pm–1:30pm Oral MDL-001 a Universal Direct Acting Antiviral for Influenza Like Illness(ILI): In Vivo Equivalence or Superiority to Oseltamivir, Nirmatrelvir and Remdesivir, In Vitro Superiority to Ribavirin Poster Hall B-C · Poster P-469 C4. Respiratory infections - viral Talk Sat Oct 24 3:30pm–3:45pm Part of Not Just Managing but Vanquishing: The New Era of Hepatitis Antivirals Oral MDL-001 a Universal Direct Acting Antiviral for Chronic Hepatitis: In Vivo Equivalence to Sofosbuvir, Single-Agent Activity Against HCV/HBV and HDV/HBV Coinfections. 103 AB HIV, sexually transmitted infections and viral hepatitisAntimicrobials, resistance and stewardship

Organization

IDWeek 2026 Attendance

Model Medicines

San Diego, CA

modelmedicines.com

Biotech

AI-driven drug discovery company developing MDL-001, an oral broad-spectrum antiviral aimed at respiratory viruses and chronic hepatitis.

Poster

Thu Oct 22
12:15pm–1:30pm

The RdRp Thumb-1 pocket is a Conserved Target for Broad-Spectrum Antiviral Development

Poster Hall B-C · Poster P-176

A6. New drug development (formerly L3)

Poster

Sat Oct 24
12:15pm–1:30pm

Oral MDL-001 a Universal Direct Acting Antiviral for Influenza Like Illness(ILI): In Vivo Equivalence or Superiority to Oseltamivir, Nirmatrelvir and Remdesivir, In Vitro Superiority to Ribavirin

Poster Hall B-C · Poster P-469

C4. Respiratory infections - viral

Talk

Sat Oct 24
3:30pm–3:45pm

Part of Not Just Managing but Vanquishing: The New Era of Hepatitis Antivirals

Oral MDL-001 a Universal Direct Acting Antiviral for Chronic Hepatitis: In Vivo Equivalence to Sofosbuvir, Single-Agent Activity Against HCV/HBV and HDV/HBV Coinfections.

103 AB

HIV, sexually transmitted infections and viral hepatitisAntimicrobials, resistance and stewardship

Instantly find 20 buyers from Model Medicines

Get a list of who you should contact, their contact info, and what to say.

Totally free and instant, no sign up necessary!

Not affiliated with or endorsed by IDWeek, the Infectious Diseases Society of America (IDSA) or its partner societies (SHEA, HIVMA, PIDS and SIDP). Submit a correction